TABLE 1.
Characteristics of MAVIDOS (Maternal Vitamin D Osteoporosis Study) mothers with a measurement of C-terminal telopeptide of type I collagen available in early or late pregnancy, in the study overall, and in the placebo group and cholecalciferol-supplemented group separately1
| All | Placebo | 1000 IU cholecalciferol/d | ||||
|---|---|---|---|---|---|---|
| Baseline characteristic | Total n | Value | Total n | Value | Total n | Value |
| Age,2 y | 607 | 30.4 ± 5.2 | 296 | 30.4 ± 5.3 | 311 | 30.3 ± 5.3 |
| Height,2 cm | 602 | 165.4 ± 6.5 | 292 | 165.5 ± 6.7 | 310 | 165.2 ± 6.4 |
| Weight,2 kg | 607 | 71.8 ± 15.0 | 296 | 72.8 ± 14.4 | 311 | 70.8 ± 15.5 |
| Pregnancy weight gain,3 kg | 536 | 9.5 ± 3.6 | 264 | 9.3 ± 3.7 | 272 | 9.7 ± 3.4 |
| 25(OH)D at 14 wk, nmol/L | 630 | 44.6 ± 16.2 | 312 | 44.1 ± 16.1 | 318 | 45.0 ± 16.3 |
| 25(OH)D at 34 wk, nmol/L | 561 | 54.2 ± 23.6 | 282 | 42.5 ± 20.6 | 279 | 66.0 ± 20.4 |
| Adjusted calcium at 14 wk, mmol/L | 630 | 2.38 ± 0.08 | 312 | 2.38 ± 0.09 | 318 | 2.37 ± 0.07 |
| Adjusted calcium at 34 wk, mmol/L | 560 | 2.34 ± 0.11 | 280 | 2.34 ± 0.12 | 280 | 2.34 ± 0.10 |
| BMI,2 kg/m2 | 602 | 24.9 [22.5–28.6] | 292 | 25.5 [22.9–29.5] | 310 | 24.4 [22.3–28.1] |
| First pregnancy | 604 | 269 (44.5) | 294 | 134 (45.6) | 310 | 135 (43.5) |
| White (Caucasian) ethnicity | 604 | 574 (95.0) | 296 | 285 (96.3) | 308 | 289 (93.8) |
| A Level or higher qualification | 602 | 450 (74.8) | 293 | 214 (73.0) | 309 | 236 (76.4) |
| Smoker2 | 605 | 54 (8.9) | 295 | 27 (9.2) | 310 | 27 (8.7) |
| More than 1 h strenuous exercise per week2 | 553 | 79 (14.3) | 270 | 33 (12.2) | 283 | 46 (16.3) |
1
Values are mean ± SD, median [IQR], or n (%) unless otherwise indicated. 25(OH)D, 25-hydroxyvitamin D.
2
Characteristics at early-pregnancy study visit.
3
Pregnancy weight gain = 34-wk maternal weight minus 14-wk maternal weight.